Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

Diabetes Care

Volumn 25, Issue 12, 2002, Pages 2244-2248

  Johnson, Jeffrey A ^a,b   Majumdar, Sumit R ^a,b   Simpson, Scot H ^b   Toth, Ellen L ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSTITUTE OF HEALTH ECONOMICS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; AGED; CANADA; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG COMBINATION; FACTUAL DATABASE; FEMALE; MALE; MIDDLE AGED; TIME;

AGED; CAUSE OF DEATH; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SASKATCHEWAN; SULFONYLUREA COMPOUNDS; TIME FACTORS;

EID: 0038279359     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.12.2244     Document Type: Article

References (26)

1. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
2. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
3. UK Prospective Diabetes Study Group: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes (UKPDS 28). Diabetes Care 21:87-92, 1998
4. Fisman EZ, Tenenbaum A, Benderly M, Goldbourt U, Behar S, Motro M: Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology 91:195-202, 1999
5. Olsson J, Lindberg G, Gottsater M, Lindwall K, Sjostrand A, Tisell A, Melander A: Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43:558-560, 2000
6. Turner RC, Holman RR: Metformin and risk of cardiovascular disease. Cardiology 91:203-204, 1999
7. Downey W, Beck P, McNutt M, Stang MR, Osei W, Nichol J: Health databases in Saskatchewan. In Pharmacoepidemiology. 3rd ed. Strom BL, Ed. Chichester, Wiley, 2000, p. 325-345
8. Tsuyuki RT, Olson KL, Teo KK: Nitroglycerin as an indicator for the presence of coronary heart disease. Can Pharm J 132:32-36, 1999
9. Von Korff M, Wagner EH, Saunders K: A chronic disease score from automated pharmacy data. J Clin Epidemiol 45:197-203, 1992
10. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303, 1999
11. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, Yae JF, Zinman B, Lillie D: 1998 clinical practice guidelines for the management of diabetes in Canada. Can Med Assoc J 159 (Suppl. 8):S1-S29, 1998
12. UK Prospective Diabetes Study Group: Risk factors for coronary artery disease in non-insulin dependent diabetes (UKPDS 23). BMJ 316:823-828, 1998
13. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
14. Gu K, Cowie C, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA 281:1291-1297, 1999
15. Coutinho M, Wang Y, Gerstein HC, Yusuf S: The relationship between glucose and incident cardiovascular events. Diabetes Care 22:233-240, 1999
16. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
17. Meinert CL, Knatterud GL, Prout TE, Klimt CR: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 19:789-830, 1970
18. Leibowitz G, Cerasi E: Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia 39:503-514, 1996
19. Feinglos MN, Bethel MA: Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am Heart J 138:S346-5352, 1999
20. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS: The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 305:865-868, 1992
21. Ray WA, Griffin ME, Downey W: Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 262:3303-3307, 1989
22. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B: Low-dose inhaled corticosteroids in the prevention of death from asthma. N Engl J Med 343:332-336, 2000
23. Stang MR, Wysowski DK, Butller-Jones D: Incidence of lactic acidosis in metformin users. Diabetes Care 22:295-297, 1999
24. Reaven GM: Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
25. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
26. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin dependent diabetes mellitus. N Engl J Med 333:550-554, 1995